Clinical-stage biotechnology company PharmAust (ASX:PAA) has executed a research services agreement with the Walter and Eliza Hall Institute in Melbourne to investigate the effects of monepantel on human T-lymphotrophic virus-1 infections in vitro. …
PharmAust and WEHI to investigate monepantel in HTLV-1 Viral Infections
July 14, 2021 Australian Biotech
Latest Video
New Stories
-
The industry walked out on Britain, and what it cost to win them back
October 22, 2026 - - Latest News -
BioNTech opens mRNA plant, putting Melbourne's north on the biotech map
October 22, 2026 - - Latest News -
An architect of the first industry–Commonwealth medicines pact to lead CSL
October 21, 2026 - - Latest News -
Quarterly update shows Telix holds course for a US$1 billion milestone year
October 21, 2026 - - Latest News -
Chemist Warehouse keeps growing as Sigma sets its sights on oral GLP-1s
October 21, 2026 - - Latest News -
America's ever rising GLP-1 curve and how Australia is following
October 21, 2026 - - Latest News -
Patient groups across Asia-Pacific push for a say on medicine prices
October 21, 2026 - - Latest News